The effect of chemotherapy on the exposure-response relation of abiraterone in metastatic castration-resistant prostate cancer.

To assess whether the exposure-response relation for abiraterone is different in pre-chemotherapy patients compared to post-chemotherapy patients with metastatic castration-resistant prostate cancer (mCRPC).